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ABSTRACT
Purpose.  Septic  shock  is  a  serious  medical  condition.  With  increased  concerns
about  invasive  techniques,  a  number  of  non-invasive  and  semi-invasive  devices
measuring cardiac output (CO) have become commercially available. The aim of the
present study was to determine the accuracy, precision and trending abilities of the
FloTrac  and  the  continuous  pulmonary  artery  catheter  thermodilution  technique
determining CO in septic shock patients.
Methods. Consecutive septic shock patients were included in two centres and CO
was measured every 4 hours up to 48 hours by FloTrac (APCO) and by pulmonary
artery catheter (PAC) using the continuous (CCO) and intermittent (ICO) technique.
Results. Forty-seven septic shock patients with 326 matched sets of APCO, CCO
and ICO data were available for analysis.  Bland and Altman analysis revealed a
mean bias ± 2SD of 0.0 ± 2.14 L min-1 for APCO-ICO (%error = 34.5%) and 0.23 ±
2.55 L min-1 for CCO-ICO (%error = 40.4%). Trend analysis showed a concordance
of 85% and 81% for APCO and CCO, respectively. In contrast to CCO, APCO  was
influenced by systemic vascular resistance and by mean arterial pressure.
Conclusions. In septic shock patients, APCO measurements assessed by FloTrac
but  also  the  established  CCO  measurements  using  the  PAC  did  not  meet  the
currently accepted statistical criteria indicating acceptable clinical performance.
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INTRODUCTION
Severe  sepsis  and septic  shock  are  serious  medical  conditions  that  still  have a
mortality  of  20  to  30% despite  contemporary  critical  care  [1].  Early  detection  of
sepsis as well as protocol-based and targeted treatment have been shown to be the
key to success in reducing mortality in the last two decades [2-4]. Sepsis leads to
organ  dysfunction  and  failure,  whereas  the  impaired  tissue  oxygenation  plays  a
central  role.  Therefore,  aggressive  fluid  and  cardiovascular  resuscitation  is  an
essential part of the therapeutic bundles of the Surviving Sepsis Campaign with the
goal of restoring organ perfusion and oxygenation early [5].
Haemodynamic monitoring is frequently used to guide and assess the response to
fluid administration and cardiovascular drug support [6]. Traditionally, cardiac output
(CO) has been measured invasively using the pulmonary artery catheter (PAC). With
increased concerns about  this invasive technique, a number of  non-invasive and
semi-invasive devices measuring CO have become commercially available [7]. Many
of  these  devices  are  based  on  pulse  wave  analysis.  Calibrated  devices  require
external calibration to account for differences and changes in vascular tone between
patients  and within  the  same patient  over  time,  respectively [8].  In  contrast,  un-
calibrated CO devices such as the FloTrac (Edwards Lifesciences, Irvine, CA, USA)
do not require external calibration [9]. Previous versions of FloTrac software have
been extensively investigated and some studies  revealed that  the  accuracy was
somewhat disappointing in hyperdynamic and vasoplegic patients [10-12]. Therefore,
the FloTrac software (third generation, G3) has been modified in order to better meet
these needs [13]. However, the accuracy, precision and trending abilities in septic
shock patients are still questionable [14-16].
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The  first aim  of  the  present  two-centre  study  was  to  determine  the  accuracy,
precision and trending abilities of the G3 software of FloTrac assessing CO in septic
shock patients. Since many clinicians use continuous CO (CCO) measurement by
PAC to assess haemodynamics in this clinical setting, the second aim was to further
report the performance of CCO in the same patient population. CO assessed by PAC
intermittent thermodilution (ICO) served as reference method.
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MATERIALS AND METHODS
This prospective, observational two-centre study was performed in the intensive care
units (ICU) of a university and a university affiliated tertiary-care hospital with local
Ethics Committee approval  (Switzerland: Kantonale Ethikkommission Zurich, KEK
Nr.  STZ  20/90; Saudi  Arabia:  King  Abdulaziz  University  Hospital  Bioethics  and
Research Committee, Nr. 150-9) after written informed consent from the patients or
their proxy. Patients were eligible for the study if they were at least 18 years old and
admitted to the ICU with the diagnosis of septic shock (according to the criteria of the
international sepsis definitions [17]). Patients were excluded from the study if they
had a body weight <40kg, aortic or tricuspid regurgitation, cardiac arrhythmias (atrial
fibrillation or flutter, and ventricular tachycardia), intra-aortic balloon pump treatment
or any contraindication to the placement of a PAC. 
Interventions and Measurements
In  all  patients the PAC (CCO  VIP Pulmonary Artery Catheter,  Model  139HF75P;
Edwards Lifesciences, Irvine, CA, USA) was inserted through the internal jugular or
subclavian vein and connected to a Vigilance monitor (Edwards Lifesciences, Irvine,
CA, USA) that allowed CO assessment by intermittent (ICO) and continuous (CCO)
thermodilution. A femoral or radial artery was cannulated and the arterial catheter
was connected to the FloTrac transducer and attached to the Vigileo monitor with the
G3  software  release  (Version  3.02; Edwards  Lifesciences,  Irvine,  CA,  USA)  for
continuous CO measurements derived from the arterial pressure waveform (APCO). 
After set-up and study initiation, CO measurements were performed and repeated
every 4 hours during a haemodynamic stable time period. ICO measurements were
done using five 10 mL boluses of normal saline with a temperature < 10°C, randomly
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injected throughout the respiratory cycle. Injectate temperature was measured at the
injection  site  using  a  CO-set  (Edwards  Lifesciences,  Irvine,  CA,  USA).  For  data
analysis the mean value of at least 3 ICO measurements with a variability <15%
were  calculated.  As  a  common,  previously  published  procedure,  single
measurements were excluded from analysis in these sets of CO measurements if
the variability was greater than 15% [18]. APCO and CCO data were recorded every
minute and the quality of the APCO signal was checked every 4 hours by square
wave test  5  min prior  to  ICO measurements.  The APCO signal  was considered
adequate  and  consecutive  measurements  were  allowed,  if  there  was  only  one
oscillation before returning to baseline after a snap flush to generate a square wave.
APCO measurements were not done, if there were two or more oscillations before
returning  to  baseline  (underdamped  curve)  or  if  no  oscillations  were  present
(overdamped  curve).  5  CCO  values  (two  before  and  three  values  after  ICO
measurement over a 5-minute period) and 15 APCO values (7 values before and 8
values  after  ICO-measurement  over  a  5-minute  period)  were  averaged.  All
hemodynamic data were automatically collected by a laptop computer connected to
both the Vigilance and Vigileo monitors for a minimum of 24 hours. 
FloTrac Algorithm
The proprietary FloTrac algorithm incorporates arterial blood pressure characteristics
to assess CO using a multivariate model based on Otto Frank’s model flow theory
that has been described in detail elsewhere [19]. Briefly, the theory states that blood
pressure fluctuates around the mean arterial pressure as a result of CO, i.e. stroke
volume (SV) that is being pumped into the vascular system during each systole.
Thus, the model has to adjust for cyclic changes of blood flow, pressure propagation
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effects,  vascular  distensibility  and  peripheral  resistance.  To  comply  with  these
requirements the FloTrac algorithm works as follows: 
1. Assessment of the contribution of pulse pressure on SV that is considered to be
proportional  to  the standard deviation (SD) of  arterial  pulse pressure.  The SD is
correlated  to  stroke  volume  using  an  underlying  database  consisting  of
anthropomorphic  and  hemodynamic  data  that  were  collected  using  the
thermodilution technique in a variety of patient populations and settings. Thus, for
the set-up of the device the input if the patient’s demographic data is required.
2. Integration of information about pulse pressure and vascular tone, primarily aortic
compliance and different statistical moments of arterial pressure including skewness
and kurtosis. Skewness and kurtosis describe arterial pressure wave symmetry and
waveform distribution, respectively. 
For the G3 algorithm update, the database was extended and more data of patients
in  septic  shock  conditions  were  included.  Moreover,  analysis  of  pulse  wave
characteristics was refined.
Statistical analysis
For  statistical  analysis  Excel  (Microsoft  Office  2008  for  Macintosh),  IBM  SPSS
Statistics (Version 2.0, Release 20.0. IBM Corp, Armonk NY, USA) and Sigmaplot
(Version 12.0, Systat, San Jose CA, USA) were used. Considering the concept of
estimating  total  analytical  error  [20]  the  subsequently  established  guidelines
recommend a minimum sample size of 120 paired samples [21]. Given the study
duration of 48 hours with a minimum number of ICO measurements of 12 per patient
and a 15% potential study protocol violation, a total of 45 patients were required in
this study.
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To describe the accuracy and agreement between intermittent CO (ICO) and the
continuous  CO  measurement  techniques  (APCO,  CCO),  a  modified  Bland  and
Altman analysis adjusted for repeated measures was done [22, 23]. Thereby, bias ±
1.96  standard  deviation  (95%  limits  of  agreement,  LOA)  was  calculated  using
random effects models with R (version 3.1.1; packages “nlme” and “MethComp”), a
software environment for statistical computing and graphics [24]. Different models
were run containing additional variables to investigate the variability in measured CO
values:  systemic vascular resistance (SVR),  mean arterial  pressure (MAP),  heart
failure (HF, i.e. patients requiring inotropic support), CO measurements < 6 L min -1
vs. ≥ 6 L min-1 (CO6), the cannulation site (i.e. radial and femoral cannulation) as well
as the two centres where the study has been performed. Percentage error (%error)
was calculated according to Critchley and Critchley considering a threshold of 30%
as indicator of a good clinical measurement performance [25]. To assess trending
abilities  of  the  continuous  measurement  techniques,  concordance  and  polar  plot
analyses using half-circle polar plots were performed as recently suggested [26-28].
Central  zone  data  (<0.5  L  min-1)  representing  statistical  noise  component  were
excluded from analysis. Trending ability was considered to be sufficient in clinical
practice if (1.) concordance was ≥ 90-95% in the 4-quadrant plot and (2.) polar plot
analysis showed an angular bias within ±5°, radial limits of agreement within ±30°,
and polar concordance rate at 30° over 95%. 
Test variability between the two centers was assessed using Student’s t-test. Unless
otherwise stated, results are presented as mean±standard deviation (SD). A p-value
< 0.05 was considered statistically significant
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RESULTS
Patient characteristics
A total of 51 patients were enrolled in the study (Switzerland: n = 24; Saudi Arabia: n
= 27), four patients had to be excluded because of severe aortic insufficiency (n = 2),
severe  intra-cardiac  left-to-right  ventricular  shunt  (n  =  1)  and  dampened  arterial
pressure wave form (n = 1) that could not be resolved. Thus, data of 47 patients
were  available  for  analysis.  Patient  characteristics  are  depicted  in  Table  1.
Haemodynamic  measurements  were  done  during  a  time  window of  39.8  ±  21.3
hours; mean time interval between subsequent intermittent CO measurements was
3.8 ± 2.2 hours.
Haemodynamics
326 matched sets of haemodynamic data were analysed in septic shock patients.
Results  are  summarized  in  Table  2.  Data  were  observed over  a  wide  range  of
haemodynamic  conditions  emphasized by the fact  that  SVR ranged from 282 to
2066 dyn sec-1 cm-5. Moreover, in 44% of all haemodynamic measurements, CO was
higher than 6 L min-1, MAP was below 70 mmHg in 40% and SVR was below 800
dyn sec-1 cm-5 in 27%. CO changes ranged from -42% to +115%, -43% to +68% and
-59%  to  +92%  for  ICO,  APCO  and  CCO,  respectively.  All  patients  received
vasoactive drug therapy support  during the study period (norepinephrine n = 46,
mean dose 22 ± 21 μg min-1; vasopressin n = 22, mean dose 0.03 ± 0.01 U min -1;
dopamine n = 13, mean dose 537 ± 192 μg min -1; Table 3). A norepinephrine dosage
of more than 30 μg min-1 was required in 21 patients (45%) and vasopressin in a
maximal dosage of 0.04 U min-1 was given in 10 patients (21%). 
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Comparison of APCO and ICO
Bland and Altman analysis for APCO vs. ICO revealed an overall mean bias ± 1.96
SD of 0.00 ± 2.14 L min-1;  bias ranged from -0.01 to 0.63 L min-1 considering all
subgroup analysis with limits of agreements between 1.74 to 2.48 L min -1 (Figure 1,
Table 4); overall %error was 34.5% and ranged from 30.5 to 35.9% for subgroup
analysis. Random effect models didn’t show any significant influence of low and high
CO (cut off 6 L min-1), heart failure with inotropic support and cannulation site (radial
vs.  femoral).  However, these models revealed the bias between APCO and ICO
measurements to be influenced by SVR and MAP: There was a significant effect of
SVR on APCO-ICO (p<0.0001) and of MAP on APCO-ICO (p=0.0007).
Trend analysis for APCO vs. ICO revealed a concordance of 85% having excluded
157 of 326 data sets (exclusion zone = 0.5 L min-1) with a significant correlation (r2 =
0.504; p = 0.005). Using polar plot analysis an angular bias of 3 ± 35° was calculated
with radial limits (95% CI) of -51 to +58°, Polar concordance at < 30° was 70% (162
of 326 data sets; exclusion zone 0.5 L min-1; Figure 2).
Comparison of CCO and ICO
Over all mean bias ± 1.96 SD for CCO vs. ICO was 0.23 ± 2.55 L min-1, bias for
subgroups was between 0.12 and 0.3 L min -1, LOA between 1.61 and 3.84 L min-1
(Figure 3, Table 5).  %error was 40.4% (overall)  with a range between 33.1 and
45.6% (subgroups). Random effect model revealed no effect on bias between CCO
and ICO measurements.
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Concordance for trends was 81% (n=155, exclusion zone = 0.5 L min-1; r2 = 0.384; p
= 0.005), angular bias was 0.1 ± 36° with radial limits (95% CI) of -57 to +57° and
polar concordance < 30° was 71% (n=155, exclusion zone = 0.5 L min-1; Figure 4).
Comparison of performance between centres
Performance  of  CO  assessment  was  comparable  between  the  two  centres:
Variability between single bolus thermodilution measurements via PAC (ICO) was 8.3
±12.4% in Switzerland and 7.7 ± 14.3% in Saudi Arabia (p = 0.09).
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DISCUSSION
In  this  study on  septic  shock  patients,  CO measurements  assessed  by  FloTrac
(APCO) and by continuous pulmonary artery catheter thermodilution (CCO) did not
meet the commonly quoted criteria for acceptability of agreement, i.e. the percentage
error was greater than 30%. Random effect  models revealed that  APCO but  not
CCO  was  slightly  influenced  by  low  SVR  and  MAP,  showing  a  tendency  to
underestimate CO in severe vasoplegia. Interestingly, the signal detection site, i.e.
radial  artery or  femoral  artery cannulation,  did  not  influence APCO. Furthermore,
trend  analysis  revealed  slightly  better  performance  for  APCO  but  still  both
techniques, APCO and CCO did not meet criteria for acceptance. APCO and CCO
cannot be used interchangeably.
In patients with septic shock the cardiovascular system is severely compromised.
Large volumes of intravenous fluids and high vasoactive and inotropic drug support
are  required  to  maintain  adequate  blood  pressure.  However,  the  diagnostic  and
prognostic value of blood pressure is limited, since it does not reflect organ blood
flow  and  thus  oxygen  delivery  to  the  tissues.  In  a  developing  hemodynamic
instability, low blood pressure is a late sign of impaired tissue perfusion, since blood
pressure is typically maintained normal for a long time by increasing the sympathetic
tone.  Therefore,  more  sensitive,  advanced  hemodynamic  monitoring  that  are
capable  of  measuring  global  blood  flow,  i.e.  CO  is  highly  warranted  to  guide
haemodynamics in this setting [29].
Despite the fact that the PAC use in clinical practice is declining [30], it is still the
established standard method for CO estimation (ICO). Since its invasiveness and its
lack to alter clinically relevant patient outcomes and costs, less invasive alternatives
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are increasingly evolving. Nevertheless, they have to be validated against the clinical
standard  prior  to  routine  use  in  critically  ill  patients  [31].  Unfortunately,  clinical
validation is not without pitfalls. Critchley et al proposed that limits of agreement are
acceptable  up  to  a  percentage error  of  ±30% between the  standard  CO (in  the
present  study ICO) and the new CO measurement technique to  be tested (here
APCO and CCO) [25]. In the present study, APCO and even the widely used CCO
technique showed a high percentage error, greater than 30% (34.5% and 40.4%,
respectively). Thus, both techniques have to be considered unreliable. However, a
recent meta-analysis showed that currently available CO devices often do not meet
these strict criteria. The threshold has been questioned and the authors of the meta-
analysis, Peyton et al, suggested that a percentage error of ±45% may be used and
argued  that  this  threshold  represent  a  more  realistic  expectation  of  achievable
precision  [32].  Taken  this  definition,  APCO  and  CCO  would  be  considered
adequately precise even in our severe vasoplegic septic patients. 
In the present study, the reference technique showed a variability of roughly 8% for
the repeated bolus measurements. Assuming an additional inherent measurement
error of 11.6% observed by Yang et al [33] the total error accounts for 20% at best.
This number is beyond the assumption that has been made for a percentage error
threshold of 30%. However, more important than the ability of a device to reliably
monitor  absolute  values  is  the  capability  to  assess  trends.  In  this  study, APCO
revealed an only moderate concordance and did not meet the proposed criteria of
the polar plot analysis. It might be important to realize that in fact neither for the 4
quadrant plot  nor the polar plot  analysis (according to Critchley et al  [26-28])  an
adjustment for multiple measurement are being made, thus there is the possibility
that a systematic error can influence results.
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Three studies so far have validated the G3 software release of FloTrac in septic
shock patients [14-16]. The present data are in accordance with the first study by De
Backer et al where they could demonstrate an acceptable bias and a percentage
error of 30% for APCO in 58 patients. Furthermore as in our results, APCO showed a
tendency to underestimate ICO in severe vasoplegic patients [14]. The second study
by Marqué et al reports a reduced accuracy in 18 patients and a percentage error
being at 64%. They argued that their population consisted of patients suffering from
even worse haemodynamic alterations requiring higher cardiovascular drug support
[15]. Our patients however were comparable in terms of vasopressor and inotropes
used. The main weakness of Marqué and colleagues study was rather that  they
compared APCO to CCO (not ICO). As shown in the present study, CCO by itself has
its own inaccuracy and imprecision. It is therefore not surprising, that their reported
bias and percentage error was much higher compared to the ones reported by our
study and the study from de Backer et al. Finally, the accuracy of the FloTrac device
in the  third study performed by Slagt et al including 19 patients was somehow in
between with bias ± 2SD of -0.2 ± 2.4 and percentage error of 53% [16]. 
The FloTrac in its previous versions was strongly influenced by SVR. Thereby, CO
was significantly underestimated in patients with severe vasoplegia [10]. It has been
postulated  that  the  differences  between  central  and  peripheral  arterial  pulse
pressures  and  the  corresponding  decrease  in  peripheral  reflection  of  the  pulse
waves might be responsible for this phenomenon (decoupling of aortic and radial
pulse pressure) [34]. Despite improved performance of the G3 software release of
FloTrac our data show that there was still a tendency to underestimate CO in low
SVR states and an influence of SVR on APCO. By contrast this could not be shown
for CCO and one might argue that therefore CCO showed a better performance,
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however, overall CCO revealed to have a high %error range (32-45%). Moreover,
results  of  trend analysis  for  CCO showed number above the thresholds that are
being used at the moment to define an acceptable device performance. 
APCO and CCO are often considered as continuous and real-time measurement
techniques. However, it has to be emphasized that this cannot be accepted as true.
For both methods there is a so-called “response time”, i.e. a time window until  a
change of CO can be seen on the monitor. This time window is required in order to
collect  sufficient  data  to  allow  for  acceptable  measurements.  In  other  words,  a
shorter sampling time will potentially increase an inherent measurement error but will
enhance  trending  capabilities.  Clearly,  the  advantage  of  APCO  is  the  fact  that
sampling time was at 60 seconds during the study period and thus, this minimally
invasive technique allows for almost real-time detection of CO changes. CCO (the
Vigilance system) on the other hand is definitively not a real time technique with
reported response times up to 10-12 minutes for the detection of 80-90% of CO
changes [35, 36]. As a consequence the two techniques cannot be directly compared
and cannot be used interchangeably in clinical practice.
The  present  study has  some limitations.  First,  we  compared APCO values from
FloTrac  to  ICO  determined  by  PAC,  since  there  is  no  better  reference  method
clinically available. CO determined by ICO measurement consists of an averaged set
of bolus thermodilution values taken from the PAC with its own imprecisions [18].
Second,  our  patients  with  massive  vasoplegia  were  treated  with  large  doses  of
different  vasopressors  to  maintain  perfusion  pressure.  We have  no  data  on  the
performance of APCO in untreated low SVR states and we cannot differentiate how
the type of vasoactive or inotropic support affected APCO performance. 
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In summary, FloTrac APCO measurements did not meet the momentarily accepted
statistical criteria in septic shock patients. Measurements seem to be influenced by
SVR, i.e. vasoplegia and APCO had a tendency to underestimate CO assessed by
bolus thermodilution. On the other hand, the established PAC CCO measurements
did  not  meet  the set  criteria  either, although measurements  did  not  seem to  be
influenced by alterations of vascular tone. Despite the present findings, the FloTrac
device may be considered as a first-line tool for patients in an early sepsis phase to
guide  haemodynamic  management.  More  invasive  CO  devices  and
echocardiography may however be warranted in prolonged haemodynamic instability
[37].
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LEGEND FOR FIGURES
Figure 1 
Title:
Bland  and Altman  analysis  for  cardiac  output  assessed by FloTrac (APCO) and
intermittent thermodilution via pulmonary artery catheter (ICO).
Footnote: 
A) Overall measurements: Solid line = bias and limits of agreement, dashed line =
95% Confidence Intervals (CI) for bias and limits of agreement.
B) Subgroup analysis (low vs. high cardiac output): Solid line = bias and limits of
agreement for ICO < 6 L min-1, dashed line = bias and limits of agreement for ICO ≥
6 L min-1.
C) Subgroup analysis (high vs. low systemic vascular resistance = SVR), solid line =
bias and limits of agreement for SVR ≥ 800 sec -1 cm-5, dashed line = bias and limits
of agreement for SVR < 800 sec-1 cm-5.
D) Subgroup analysis (cannulation sites), solid line = bias and limits of agreement for
radial artery cannulation site, dashed line = bias and limits of agreement for femoral
artery cannulation site.
All numbers are depicted in Table 4 in detail.
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Figure 2
Title:
Trend  analysis  for  changes  in  cardiac  output  assessed  by FloTrac  (APCO)  and
intermittent thermodilution via pulmonary artery catheter (ICO).
Footnote: 
Four quadrant plot: Concordance = 85% (n = 165, exclusion zone = 0.5 L min -1);
solid line = regression line (r2 = 0.504; p = 0.005). Semilunar polar plot: dashed lines:
angular bias = 3±35° and radial limits (95% CI) = -51 to +58°; polar concordance at <
30° = 70% (n = 162; exclusion zone = 0.5 L min-1).
Figure 3
Title:
Bland and Altman analysis for CO assessed by continuous (CCO) and intermittent
(ICO) thermodilution via pulmonary artery catheter.
Footnote: 
A) Overall measurements: Solid line = bias and limits of agreement, dashed line =
95% Confidence Intervals (CI) for bias and limits of agreement
B) Subgroup analysis (low vs. high cardiac output): Solid line = bias and limits of
agreement for ICO < 6 L min-1, dashed line = bias and limits of agreement for ICO ≥
6 L min-1.
C) Subgroup analysis (high vs. low systemic vascular resistance = SVR), solid line =
bias and limits of agreement for SVR ≥ 800 sec -1 cm-5, dashed line = bias and limits
of agreement for SVR < 800 sec-1 cm-5.
All numbers are depicted in Table 5 in detail.
25
Figure 4
Title:
Trend  analysis  for  CO changes  assessed  by continuous  (CCO)  and  intermittent
(ICO) thermodilution via pulmonary artery catheter.
Footnote:
Four quadrant plot: Concordance = 81% (n = 155, exclusion zone = 0.5 L min -1);
solid line = regression line (r2 = 0.384; p = 0.005). Semilunar polar plot: dashed lines:
angular bias = 0.1±36° and radial limits (95% CI) = -57 to +57°; polar concordance at
< 30° = 71% (n = 155; exclusion zone = 0.5 L min-1). 
26
Table 1: Patient characteristics
___________________________________________________________________
Sociodemographic
F / M ratio n/n 18 / 31
Age years 61.4±16.9
Weight kg 73.7±14.9
Height cm 164.5±8.8
BSA m2 1.8±0.2
BMI kg m-2 27.2±4.5
History of disease
CAD n (%) 18 (37)
Heart failure n (%) 13 (27)
DM II n (%) 22 (45)
Hypertension n (%) 19 (39)
Renal insufficiency n (%) 16 (33)
Malignancy n (%) 6 (12)
Other Systemic Disease n (%) 28 (57)
Patient type
Medical/Surgical ICU n/n 31 / 18
Cause of septic shock 
Pneumonia n (%) 21 (43)
Intraabdominal infection n (%) 8 (16)
Urinary tract infection n (%) 10 (20)
Other n (%) 9 (18)
___________________________________________________________________
BMI = Body mass index, BSA = Body surface area, CAD = Coronary artery disease,
DM = Diabetes mellitus, F/M = female / male
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Table 2: Haemodynamic data during the study period
___________________________________________________________________
HR beats min-1 95±21 (40-167)
MAP mmHg 73±10 (35-100)
ICO L min-1 6.0±2.3 (1.5-19.7)
ΔICO L min-1 -0.1±1.2 (-4.3-9.2)
APCO L min-1 6.2±1.8 (2.5-16.5)
ΔAPCO L min-1 -0.1±1.0 (-4.7-4.3)
CCO L min-1 6.4±2.3 (1.5-18.4)
ΔCCO L min-1 -0.1±1.4 (-11.7-3.6)
SVR dyn sec-1 cm-5 1017±336 (282-2066)
___________________________________________________________________
APCO  =  Cardiac  output  (CO)  assessed  by  Flotrac,  CCO  =  CO  assessed  by
continuous thermodilution via pulmonary artery catheter, HR = Heart rate, ICO = CO
assessed by intermittent thermodilution via pulmonary artery catheter, MAP = Mean
arterial  pressure,  SVR = Systemic vascular  resistance.  (  )  =  Range of  observed
values.
28
Table 3: Vasoactive and inotropic drug support during the study period
___________________________________________________________________
Norepinephrine n (%) 46 (98.0)
ug/min 22±21
Vasopressin n (%) 22 (44.9)
ug/min 0.03±0.01
Dopamine n (%) 13 (27.1)
ug/min 537±192
Dobutamine n (%) 32 (65.3)
ug/min 200±150
Milrinone n (%) 6 (12.3)
ug/min 570±260
Levosimendan n (%) 0 (0)
___________________________________________________________________
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Table 4: Bland and Altman analysis and percentage error for APCO versus ICO
_______________________________________________________________________________________________________
Mean bias (95%CI) lower LOA (95%CI) upper LOA (95%CI) %error (*)    
_______________________________________________________________________________________________________
Overall 0.00 (-0.24/0.24) -2.14 (-2.38/-1.90) 2.14 (1.90/2.38) 34.5 (25.5 - 44.5)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ICO <6 L/min 0.27 (0.02/0.52) -1.48 (-1.73/-1.23) 2.01 (1.76/2.26) 35.8 (24.8 - 47.5)
ICO >6 L/min -0.41 (-0.81/-0.02) -2.88 (-3.28/-2.49) 2.06 (1.66/2.45) 32.3 (21.3 - 43.9)
MAP >70 mmHg 0.10 (-0.21/0.40) -2.08 (-2.39/-1.77) 2.28 (1.97/2.58) 35.0 (24.0 - 47.1)
MAP <70 mmHg -0.16 (-0.44/0.13) -2.37 (-2.65/-2.09) 2.06 (1.77/2.34) 30.9 (25.4 - 47.6)
SVR >800 dyn/sec/cm5 0.27 (0.02/0.53) -1.65 (-1.91/-1.40) 2.19 (1.94/2.45) 35.9 (30.0 - 54.0)
SVR <800 dyn/sec/cm5 -0.63(-1.03/-0.22) -3.11 (-3.51/-2.71) 1.85 (1.45/2.26) 30.5 (19.9 - 39.8)
No Heart failure -0.02 (-0.29/0.24) -2.22 (-2.49/-1.96) 2.18 (1.91/2.44) 34.6 (24.9 - 45.6)
Heart failure -0.01 (-0.51/0.50) -2.07 (-2.57/-1.56) 2.05 (1.55/2.56) 34.2 (19.7 - 53.1)
Radial cannulation -0.04 (-0.38/0.29) -2.11(-2.44/-1.77) 2.02 (1.69/2.36) 34.6 (22.5 - 48.4)
Femoral cannulation 0.04 (-0.31/0.38) -2.18 (-2.53/-1.84) 2.26 (1.91/2.61) 34.9 (22.9 - 48.3)
________________________________________________________________________________________________________
APCO = Cardiac output (CO) assessed by Flotrac; ICO = CO assessed by intermittent thermodilution via pulmonary artery catheter; LOA
= limits of agreement; MAP = Mean arterial pressure, SVR = Systemic vascular resistance; %error = percentage error: * considering 95%
CI of (APCO+ICO)/2 and LOA’s
Table 5: Bland and Altman analysis and percentage error for CCO versus ICO
_______________________________________________________________________________________________________
Mean bias (95%CI) lower LOA (95%CI) upper LOA (95%CI) %error (*)    
_______________________________________________________________________________________________________
Overall 0.23 (0.00/0.46) -2.32 (-2.55/-2.09) 2.78 (2.55/3.02) 40.4 (31.5 - 50.3)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ICO <6 L/min 0.25 (0.03/0.47) -1.36 (-1.58/-1.14) 1.86 (1.64/2.08) 33.1 (23.2 - 43.8)
ICO >6 L/min 0.13 (-0.28/0.53) -3.20 (-3.61/-2.80) 3.46 (3.05/3.86) 42.2 (31.0 - 53.9)
MAP >70 mmHg 0.24 (-0.04/0.51) -2.14 (-2.42/-1.86) 2.61 (2.34/2.89) 37.4 (27.4 - 48.9)
MAP <70 mmHg 0.15 (-0.14/0.45) -2.61 (-2.91/-2.32) 2.92 (2.62/3.21) 44.1 (32.9 - 56.1)
SVR >800 dyn/sec/cm5 0.30 (0.08/0.52) -1.49 (-1.72/-1.27) 2.09 (1.87/2.32) 33.2 (16.2 - 28.8)
SVR <800 dyn/sec/cm5 0.12 (-0.33/0.57) -3.73 (-4.18/-3.27) 3.96 (3.52/4.42) 45.6 (53.5 - 91.3)
No Heart failure 0.21 (-0.04/0.47) -2.30 (-2.56/-2.05) 2.73 (2.47/2.98) 38.5 (32.3 - 40.7)
Heart failure 0.24 (-0.27/0.75) -2.49 (-3.01/-1.98) 2.97 (2.46/3.48) 45.1 (36.2 - 64.6)
________________________________________________________________________________________________________
CCO = CO assessed by continuous thermodilution via pulmonary artery catheter; ICO = CO assessed by intermittent thermodilution via
pulmonary artery catheter;  LOA = limits of agreement; MAP = Mean arterial pressure; SVR = Systemic vascular resistance; %error =
percentage error: * considering 95% CI of (APCO+ICO)/2 and LOA’s
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